{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T02:44:48Z","timestamp":1788576288780,"version":"build-2803163510"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00213-025-06767-1","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:07:11Z","timestamp":1743368831000},"page":"1669-1691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Orexin receptors: possible therapeutic targets for psychiatric disorders"],"prefix":"10.1007","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4444-2911","authenticated-orcid":false,"given":"Shigeyuki","family":"Chaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"6767_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13651501.2019.1711425","volume":"24","author":"\u00d6F Ak\u00e7a","year":"2020","unstructured":"Ak\u00e7a \u00d6F, Uzun N, K\u0131l\u0131n\u00e7 \u0130 (2020) Orexin A in adolescents with anxiety disorders. Int J Psychiatry Clin Pract 24:127\u2013134. https:\/\/doi.org\/10.1080\/13651501.2019.1711425","journal-title":"Int J Psychiatry Clin Pract"},{"key":"6767_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fnins.2014.00033","volume":"8","author":"RI Anderson","year":"2014","unstructured":"Anderson RI, Becker HC, Adams BL, Jesudason CD, Rorick-Kehn LM (2014) Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. Front Neurosci 8:33. https:\/\/doi.org\/10.3389\/fnins.2014.00033","journal-title":"Front Neurosci"},{"issue":"Suppl 1","key":"6767_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuropharm.2008.06.060","volume":"56","author":"G Aston-Jones","year":"2009","unstructured":"Aston-Jones G, Smith RJ, Moorman DE, Richardson KA (2009) Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 56(Suppl 1):112\u2013121. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.06.060","journal-title":"Neuropharmacology"},{"key":"6767_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ams2.368","volume":"5","author":"K Azuma","year":"2018","unstructured":"Azuma K, Takaesu Y, Soeda H, Iguchi A, Uchida K, Ohta S, Mishima S, Inoue T, Inoue Y, Oda J (2018) Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg 5:362\u2013368. https:\/\/doi.org\/10.1002\/ams2.368","journal-title":"Acute Med Surg"},{"key":"6767_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10072-018-3692-8","volume":"40","author":"S Baykal","year":"2019","unstructured":"Baykal S, Albayrak Y, Duranku\u015f F, G\u00fczel S, Abbak \u00d6, Potas N, Beyazy\u00fcz M, Karabekiro\u011flu K, Donma MM (2019) Decreased serum orexin A levels in drug-naive children with attention deficit and hyperactivity disorder. Neurol Sci 40:593\u2013602. https:\/\/doi.org\/10.1007\/s10072-018-3692-8","journal-title":"Neurol Sci"},{"key":"6767_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","volume":"354","author":"P Bonaventure","year":"2015","unstructured":"Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N, Chaplan SR, Aguilar Z, Halter R, Ndifor A, Koudriakova T, Rizzolio M, Letavic M, Carruthers NI, Lovenberg T, Dugovic C (2015) Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia. J Pharmacol Exp Ther 354:471\u2013482. https:\/\/doi.org\/10.1124\/jpet.115.225466","journal-title":"J Pharmacol Exp Ther"},{"key":"6767_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10388-017-0570-z","volume":"14","author":"E Booka","year":"2017","unstructured":"Booka E, Tsubosa Y, Matsumoto T, Takeuchi M, Kitani T, Nagaoka M, Imai A, Kamijo T, Iida Y, Shimada A, Takebayashi K, Niihara M, Mori K, Onitsuka T, Takeuchi H, Kitagawa Y (2017) Postoperative delirium after pharyngolaryngectomy with esophagectomy: a role for ramelteon and suvorexant. Esophagus 14:229\u2013234. https:\/\/doi.org\/10.1007\/s10388-017-0570-z","journal-title":"Esophagus"},{"key":"6767_CR8","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1017\/S1461145713000333","volume":"16","author":"RM Brown","year":"2013","unstructured":"Brown RM, Khoo SY, Lawrence AJ (2013) Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. Int J Neuropsychopharmacol 16:2067\u20132079. https:\/\/doi.org\/10.1017\/S1461145713000333","journal-title":"Int J Neuropsychopharmacol"},{"key":"6767_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/adb.12251","volume":"21","author":"RM Brown","year":"2016","unstructured":"Brown RM, Kim AK, Khoo SY, Kim JH, Jupp B, Lawrence AJ (2016) Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats. Addict Biol 21:603\u2013612. https:\/\/doi.org\/10.1111\/adb.12251","journal-title":"Addict Biol"},{"key":"6767_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.euroneuro.2007.01.005","volume":"17","author":"L Brundin","year":"2007","unstructured":"Brundin L, Bj\u00f6rkqvist M, Peters\u00e9n A, Tr\u00e4skman-Bendz L (2007) Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol 17:573\u2013579. https:\/\/doi.org\/10.1016\/j.euroneuro.2007.01.005","journal-title":"Eur Neuropsychopharmacol"},{"key":"6767_CR11","doi-asserted-by":"publisher","unstructured":"Campbell EJ, Marchant NJ, Lawrence AJ (2020) A sleeping giant: Suvorexant for the treatment of alcohol use disorder? Brain Res 1731:145902. https:\/\/doi.org\/10.1016\/j.brainres.2018.08.005","DOI":"10.1016\/j.brainres.2018.08.005"},{"key":"6767_CR12","doi-asserted-by":"publisher","unstructured":"Campbell EJ, Bonomo Y, Collins L, Norman A, O\u2019Neill H, Streitberg A, Galloway K, Kyoong A, Perkins A, Pastor A, Lawrence AJ (2024) The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report. Clin Case Rep 12:e8740. https:\/\/doi.org\/10.1002\/ccr3.8740","DOI":"10.1002\/ccr3.8740"},{"key":"6767_CR13","doi-asserted-by":"publisher","unstructured":"Chaki S (2024) Melanin-concentrating hormone receptor: A therapeutic target for novel anxiolytics. Pharmacol Biochem Behav 242:173818. https:\/\/doi.org\/10.1016\/j.pbb.2024.173818","DOI":"10.1016\/j.pbb.2024.173818"},{"key":"6767_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.pbb.2015.05.018","volume":"135","author":"S Chaki","year":"2015","unstructured":"Chaki S, Shimazaki T, Nishiguchi M, Funakoshi T, Iijima M, Ito A, Kanuma K, Sekiguchi Y (2015) Antidepressant\/anxiolytic potential and adverse effect liabilities of melanin-concentrating hormone receptor 1 antagonists in animal models. Pharmacol Biochem Behav 135:154\u2013168. https:\/\/doi.org\/10.1016\/j.pbb.2015.05.018","journal-title":"Pharmacol Biochem Behav"},{"key":"6767_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0092-8674(00)81973-x","volume":"98","author":"RM Chemelli","year":"1999","unstructured":"Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437\u2013451. https:\/\/doi.org\/10.1016\/s0092-8674(00)81973-x","journal-title":"Cell"},{"key":"6767_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jad.2023.01.031","volume":"325","author":"B Chen","year":"2023","unstructured":"Chen B, Xu J, Chen S, Mou T, Wang Y, Wang H, Zhang Z, Ren F, Wang Z, Jin K, Lu J (2023) Dysregulation of striatal dopamine D2\/D3 receptor-mediated by hypocretin induces depressive behaviors in rats. J Affect Disord 325:256\u2013263. https:\/\/doi.org\/10.1016\/j.jad.2023.01.031","journal-title":"J Affect Disord"},{"key":"6767_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811231225610","volume":"38","author":"PY Chen","year":"2024","unstructured":"Chen PY, Chiu CC, Chang CK, Lu ML, Huang CY, Chen CH, Huang MC (2024) Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study. J Psychopharmacol 38:258\u2013267. https:\/\/doi.org\/10.1177\/02698811231225610","journal-title":"J Psychopharmacol"},{"key":"6767_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psyneuen.2014.12.012","volume":"53","author":"YL Chien","year":"2015","unstructured":"Chien YL, Liu CM, Shan JC, Lee HJ, Hsieh MH, Hwu HG, Chiou LC (2015) Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology 53:1\u20139. https:\/\/doi.org\/10.1016\/j.psyneuen.2014.12.012","journal-title":"Psychoneuroendocrinology"},{"key":"6767_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ijnp\/pyx033","volume":"20","author":"KM Connor","year":"2017","unstructured":"Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, Thase M, Lines C, Herring WJ, Michelson D (2017) Phase II proof-of-concept trial of the orexin receptor antagonist Filorexant (MK-6096) in patients with major depressive disorder. Int J Neuropsychopharmacol 20:613\u2013618. https:\/\/doi.org\/10.1093\/ijnp\/pyx033","journal-title":"Int J Neuropsychopharmacol"},{"key":"6767_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4088\/jcp.v66n0401","volume":"66","author":"W Coryell","year":"2005","unstructured":"Coryell W, Young EA (2005) Clinical predictors of suicide in primary major depressive disorder. J Clin Psychiatry 66:412\u2013417. https:\/\/doi.org\/10.4088\/jcp.v66n0401","journal-title":"J Clin Psychiatry"},{"key":"6767_CR21","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","volume":"53","author":"CD Cox","year":"2010","unstructured":"Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, Bruno JG, Reiss DR, Harrell CM, Murphy KL, Garson SL, Doran SM, Prueksaritanont T, Anderson WB, Tang C, Roller S, Cabalu TD, Cui D, Hartman GD, Young SD, Koblan KS, Winrow CJ, Renger JJ, Coleman PJ (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H\u20131,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53:5320\u20135332. https:\/\/doi.org\/10.1021\/jm100541c","journal-title":"J Med Chem"},{"key":"6767_CR22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","volume":"95","author":"L de Lecea","year":"1998","unstructured":"de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322\u2013327. https:\/\/doi.org\/10.1073\/pnas.95.1.322","journal-title":"Proc Natl Acad Sci USA"},{"key":"6767_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110517","volume":"116","author":"A Demidova","year":"2022","unstructured":"Demidova A, Kahl E, Fendt M (2022) Orexin deficiency affects sensorimotor gating and its amphetamine-induced impairment. Prog Neuropsychopharmacol Biol Psychiatry 116:110517","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6767_CR24","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41398-021-01235-8","volume":"11","author":"HB Elam","year":"2021","unstructured":"Elam HB, Perez SM, Donegan JJ, Lodge DJ (2021) Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis. Transl Psychiatry 11:114. https:\/\/doi.org\/10.1038\/s41398-021-01235-8","journal-title":"Transl Psychiatry"},{"key":"6767_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neuro.2021.02.005","volume":"84","author":"P Esmaili-Shahzade-Ali-Akbari","year":"2021","unstructured":"Esmaili-Shahzade-Ali-Akbari P, Hosseinzadeh H, Mehri S (2021) Effect of suvorexant on morphine tolerance and dependence in mice: Role of NMDA, AMPA, ERK and CREB proteins. Neurotoxicology 84:64\u201372. https:\/\/doi.org\/10.1016\/j.neuro.2021.02.005","journal-title":"Neurotoxicology"},{"key":"6767_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1460-9568.2009.07065.x","volume":"31","author":"RA Espa\u00f1a","year":"2010","unstructured":"Espa\u00f1a RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR (2010) The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. Eur J Neurosci 31:336\u2013348. https:\/\/doi.org\/10.1111\/j.1460-9568.2009.07065.x","journal-title":"Eur J Neurosci"},{"key":"6767_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnins.2014.00005","volume":"8","author":"TE Fitch","year":"2014","unstructured":"Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA, Rorick-Kehn LM (2014) LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci 8:5. https:\/\/doi.org\/10.3389\/fnins.2014.00005","journal-title":"Front Neurosci"},{"key":"6767_CR28","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1038\/npp.2014.146","volume":"39","author":"\u00c1 Flores","year":"2014","unstructured":"Flores \u00c1, Valls-Comamala V, Costa G, Saravia R, Maldonado R, Berrendero F (2014) The hypocretin\/orexin system mediates the extinction of fear memories. Neuropsychopharmacology 39:2732\u20132741. https:\/\/doi.org\/10.1038\/npp.2014.146","journal-title":"Neuropsychopharmacology"},{"key":"6767_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.tins.2015.06.005","volume":"38","author":"\u00c1 Flores","year":"2015","unstructured":"Flores \u00c1, Saravia R, Maldonado R, Berrendero F (2015) Orexins and fear: implications for the treatment of anxiety disorders. Trends Neurosci 38:550\u2013559. https:\/\/doi.org\/10.1016\/j.tins.2015.06.005","journal-title":"Trends Neurosci"},{"key":"6767_CR30","doi-asserted-by":"publisher","first-page":"1085882","DOI":"10.3389\/fnbeh.2022.1085882","volume":"16","author":"FJ Flores-Ramirez","year":"2022","unstructured":"Flores-Ramirez FJ, Illenberger JM, Pascasio GE, Matzeu A, Mason BJ, Martin-Fardon R (2022) Alternative use of suvorexant (Belsomra\u00ae) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence. Front Behav Neurosci 16:1085882. https:\/\/doi.org\/10.3389\/fnbeh.2022.1085882","journal-title":"Front Behav Neurosci"},{"key":"6767_CR31","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/bph.16015","volume":"180","author":"FJ Flores-Ramirez","year":"2023","unstructured":"Flores-Ramirez FJ, Varodayan FP, Patel RR, Illenberger JM, Di Ottavio F, Roberto M, Martin-Fardon R (2023) Blockade of orexin receptors in the infralimbic cortex prevents stress-induced reinstatement of alcohol-seeking behaviour in alcohol-dependent rats. Br J Pharmacol 180:1500\u20131515. https:\/\/doi.org\/10.1111\/bph.16015","journal-title":"Br J Pharmacol"},{"key":"6767_CR32","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/s41386-019-0420-x","volume":"44","author":"JE Fragale","year":"2019","unstructured":"Fragale JE, Pantazis CB, James MH, Aston-Jones G (2019) The role of orexin-1 receptor signaling in demand for the opioid fentanyl. Neuropsychopharmacology 44:1690\u20131697. https:\/\/doi.org\/10.1038\/s41386-019-0420-x","journal-title":"Neuropsychopharmacology"},{"key":"6767_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115489","volume":"28","author":"A Futamura","year":"2020","unstructured":"Futamura A, Suzuki R, Tamura Y, Kawamoto H, Ohmichi M, Hino N, Tokumaru Y, Kirinuki S, Hiyoshi T, Aoki T, Kambe D, Nozawa D (2020) Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia. Bioorg Med Chem 28:115489. https:\/\/doi.org\/10.1016\/j.bmc.2020.115489","journal-title":"Bioorg Med Chem"},{"key":"6767_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/adb.12507","volume":"23","author":"TA Gentile","year":"2018","unstructured":"Gentile TA, Simmons SJ, Barker DJ, Shaw JK, Espa\u00f1a RA, Muschamp JW (2018) Suvorexant, an orexin\/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addict Biol 23:247\u2013255. https:\/\/doi.org\/10.1111\/adb.12507","journal-title":"Addict Biol"},{"key":"6767_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41398-022-02090-x","volume":"12","author":"SM Gorka","year":"2022","unstructured":"Gorka SM, Khorrami KJ, Manzler CA, Phan KL (2022) Acute orexin antagonism selectively modulates anticipatory anxiety in humans: implications for addiction and anxiety. Transl Psychiatry 12:308. https:\/\/doi.org\/10.1038\/s41398-022-02090-x","journal-title":"Transl Psychiatry"},{"key":"6767_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuroscience.2017.02.038","volume":"348","author":"LA Grafe","year":"2017","unstructured":"Grafe LA, Eacret D, Luz S, Gotter AL, Renger JJ, Winrow CJ, Bhatnagar S (2017) Orexin 2 receptor regulation of the hypothalamic-pituitary-adrenal (HPA) response to acute and repeated stress. Neuroscience 348:313\u2013323. https:\/\/doi.org\/10.1016\/j.neuroscience.2017.02.038","journal-title":"Neuroscience"},{"key":"6767_CR37","doi-asserted-by":"publisher","unstructured":"Grafe LA, Eacret D, Dobkin J, Bhatnagar S (2018) Reduced Orexin System Function Contributes to Resilience to Repeated Social Stress. eNeuro 5:ENEURO.0273\u201317.2018. https:\/\/doi.org\/10.1523\/ENEURO.0273-17.2018.","DOI":"10.1523\/ENEURO.0273-17.2018"},{"key":"6767_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jneuroim.2015.11.014","volume":"290","author":"MY Hamasaki","year":"2016","unstructured":"Hamasaki MY, Barbeiro HV, Barbeiro DF, Cunha DM, Koike MK, Machado MC, Pinheiro da Silva F (2016) Neuropeptides in the brain defense against distant organ damage. J Neuroimmunol 290:33\u201335. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.11.014","journal-title":"J Neuroimmunol"},{"key":"6767_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0896-6273(01)00293-8","volume":"30","author":"J Hara","year":"2001","unstructured":"Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345\u2013354. https:\/\/doi.org\/10.1016\/s0896-6273(01)00293-8","journal-title":"Neuron"},{"key":"6767_CR40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature04071","volume":"437","author":"GC Harris","year":"2005","unstructured":"Harris GC, Wimmer M, Aston-Jones G (2005) A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437:556\u2013559. https:\/\/doi.org\/10.1038\/nature04071","journal-title":"Nature"},{"key":"6767_CR41","doi-asserted-by":"publisher","first-page":"e970","DOI":"10.4088\/JCP.16m11194","volume":"78","author":"Hatta K, Kishi Y, Wada K, Takeuchi T, Ito S, Kurata A, Murakami K, Sugita M, Usui C, Nakamura H; DELIRIA-J Group","year":"2017","unstructured":"Hatta K, Kishi Y, Wada K, Takeuchi T, Ito S, Kurata A, Murakami K, Sugita M, Usui C, Nakamura H; DELIRIA-J Group (2017) Preventive effects of Suvorexant on delirium: A randomized placebo-controlled trial. J Clin Psychiatry 78:e970\u2013e979. https:\/\/doi.org\/10.4088\/JCP.16m11194","journal-title":"J Clin Psychiatry"},{"key":"6767_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27691","volume":"7","author":"Hatta K, Kishi Y, Wada K, Takeuchi T, Taira T, Uemura K, Ogawa A, Takahashi K, Sato A, Shirakawa M, Herring WJ, Arano I; Suvorexant 085 Study Group","year":"2024","unstructured":"Hatta K, Kishi Y, Wada K, Takeuchi T, Taira T, Uemura K, Ogawa A, Takahashi K, Sato A, Shirakawa M, Herring WJ, Arano I; Suvorexant 085 Study Group (2024) Suvorexant for reduction of delirium in older adults after hospitalization: A randomized clinical trial. JAMA Netw Open 7:e2427691. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.27691","journal-title":"JAMA Netw Open"},{"key":"6767_CR43","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.tips.2003.09.011","volume":"24","author":"A Holmes","year":"2003","unstructured":"Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G (2003) Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24:580\u2013588. https:\/\/doi.org\/10.1016\/j.tips.2003.09.011","journal-title":"Trends Pharmacol Sci"},{"key":"6767_CR44","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, Kapur S (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776\u2013786. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2012.169","journal-title":"Arch Gen Psychiatry"},{"key":"6767_CR45","doi-asserted-by":"publisher","unstructured":"Huhn AS, Finan PH, Gamaldo CE, Hammond AS, Umbricht A, Bergeria CL, Strain EC, Dunn KE (2022) Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. Sci Transl Med 14:eabn8238. https:\/\/doi.org\/10.1126\/scitranslmed.abn8238.","DOI":"10.1126\/scitranslmed.abn8238"},{"key":"6767_CR46","doi-asserted-by":"publisher","first-page":"1127735","DOI":"10.3389\/fphar.2023.1127735","volume":"14","author":"JM Illenberger","year":"2023","unstructured":"Illenberger JM, Flores-Ramirez FJ, Matzeu A, Mason BJ, Martin-Fardon R (2023) Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats. Front Pharmacol 14:1127735. https:\/\/doi.org\/10.3389\/fphar.2023.1127735","journal-title":"Front Pharmacol"},{"key":"6767_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/02698811241260989","volume":"38","author":"JM Illenberger","year":"2024","unstructured":"Illenberger JM, Flores-Ramirez FJ, Pascasio G, Franco M, Mendonsa B, Martin-Fardon R (2024) Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior. J Psychopharmacol 38:647\u2013660. https:\/\/doi.org\/10.1177\/02698811241260989","journal-title":"J Psychopharmacol"},{"key":"6767_CR48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.peptides.2004.10.014","volume":"26","author":"M Ishibashi","year":"2005","unstructured":"Ishibashi M, Takano S, Yanagida H, Takatsuna M, Nakajima K, Oomura Y, Wayner MJ, Sasaki K (2005) Effects of orexins\/hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats in vitro. Peptides 26:471\u2013481. https:\/\/doi.org\/10.1016\/j.peptides.2004.10.014","journal-title":"Peptides"},{"key":"6767_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108359","volume":"183","author":"MH James","year":"2021","unstructured":"James MH, Fragale JE, O\u2019Connor SL, Zimmer BA, Aston-Jones G (2021) The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 183:108359. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108359","journal-title":"Neuropharmacology"},{"key":"6767_CR50","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41380-018-0127-0","volume":"24","author":"MJ Ji","year":"2019","unstructured":"Ji MJ, Zhang XY, Chen Z, Wang JJ, Zhu JN (2019) Orexin prevents depressive-like behavior by promoting stress resilience. Mol Psychiatry 24:282\u2013293. https:\/\/doi.org\/10.1038\/s41380-018-0127-0","journal-title":"Mol Psychiatry"},{"key":"6767_CR51","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jad.2020.08.024","volume":"277","author":"K Jin","year":"2020","unstructured":"Jin K, Lu J, Yu Z, Shen Z, Li H, Mou T, Xu Y, Huang M (2020) Linking peripheral IL-6, IL-1\u03b2 and hypocretin-1 with cognitive impairment from major depression. J Affect Disord 277:204\u2013211. https:\/\/doi.org\/10.1016\/j.jad.2020.08.024","journal-title":"J Affect Disord"},{"key":"6767_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nm.2075","volume":"16","author":"PL Johnson","year":"2010","unstructured":"Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, Tr\u00e4skman-Bendz L, Goddard AW, Brundin L, Shekhar A (2010) A key role for orexin in panic anxiety. Nat Med 16:111\u2013115. https:\/\/doi.org\/10.1038\/nm.2075","journal-title":"Nat Med"},{"key":"6767_CR53","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/da.22403","volume":"32","author":"PL Johnson","year":"2015","unstructured":"Johnson PL, Federici LM, Fitz SD, Renger JJ, Shireman B, Winrow CJ, Bonaventure P, Shekhar A (2015) Orexin 1 and 2 receptor involvement in CO2-induced panic-associated behavior and autonomic responses. Depress Anxiety 32:671\u2013683. https:\/\/doi.org\/10.1002\/da.22403","journal-title":"Depress Anxiety"},{"key":"6767_CR54","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bcpt.13930","volume":"133","author":"D Kambe","year":"2023","unstructured":"Kambe D, Hasegawa S, Imadera Y, Mano Y, Matsushita I, Konno Y, Ogo H, Uchimura N, Uchiyama M (2023) Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: Randomized, double-blind, placebo-controlled phase-1 studies. Basic Clin Pharmacol Toxicol 133:576\u2013591. https:\/\/doi.org\/10.1111\/bcpt.13930","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6767_CR55","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jpsychires.2020.05.017","volume":"128","author":"M Kamiya","year":"2020","unstructured":"Kamiya M, Sabia HD, Marella J, Fava M, Nemeroff CB, Umeuchi H, Iijima M, Chaki S, Nishino I (2020) Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. J Psychiatr Res 128:43\u201351. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.05.017","journal-title":"J Psychiatr Res"},{"key":"6767_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.110166","volume":"108","author":"P Kaufmann","year":"2021","unstructured":"Kaufmann P, Ort M, Golor G, Kornberger R, Dingemanse J (2021) Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313. Prog Neuropsychopharmacol Biol Psychiatry 108:110166. https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110166","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6767_CR57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.09.024","volume":"28","author":"K Kawada","year":"2019","unstructured":"Kawada K, Ohta T, Tanaka K, Miyamura M, Tanaka S (2019) Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients. J Stroke Cerebrovasc Dis 28:142\u2013148. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.09.024","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"6767_CR58","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jpsychires.2021.12.027","volume":"145","author":"I Kobayashi","year":"2021","unstructured":"Kobayashi I, Mellman TA, Cannon A, Brown I, Boadi L, Howell MK, Lavela P, Sandhu I (2021) Blocking the orexin system following therapeutic exposure promoted between session habituation, but not PTSD symptom reduction. J Psychiatr Res 145:222\u2013229. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.12.027","journal-title":"J Psychiatr Res"},{"key":"6767_CR59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4183\/aeb.2019.16","volume":"5","author":"L Kobylinska","year":"2019","unstructured":"Kobylinska L, Panaitescu AM, Gabreanu G, Anghel CG, Mihailescu I, Rad F, Nedelcu C, Mocanu I, Constantin C, Badescu SV, Dobrescu I, Neagu M, Geicu OI, Zagrean L, Zagrean AM (2019) Plasmatic levels of neuropeptides, including oxytocin, in children with autism spectrum disorder, correlate with the disorder severity. Acta Endocrinol (Buchar) 5:16\u201324. https:\/\/doi.org\/10.4183\/aeb.2019.16","journal-title":"Acta Endocrinol (Buchar)"},{"key":"6767_CR60","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/da.22530","volume":"33","author":"CS Kogan","year":"2016","unstructured":"Kogan CS, Stein DJ, Maj M, First MB, Emmelkamp PM, Reed GM (2016) The classification of anxiety and fear-related disorders in the ICD-11. Depress Anxiety 33:1141\u20131154. https:\/\/doi.org\/10.1002\/da.22530","journal-title":"Depress Anxiety"},{"key":"6767_CR61","doi-asserted-by":"publisher","unstructured":"Lai KY, Li CJ, Tsai CS, Chou WJ, Huang WT, You HL, Lee SY, Wang LJ (2024) Appetite hormones, neuropsychological function and methylphenidate use in children with attention-deficit\/hyperactivity disorder. Psychoneuroendocrinology 170:107169. https:\/\/doi.org\/10.1016\/j.psyneuen.2024.107169","DOI":"10.1016\/j.psyneuen.2024.107169"},{"key":"6767_CR62","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/sj.bjp.0706789","volume":"148","author":"AJ Lawrence","year":"2006","unstructured":"Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B (2006) The orexin system regulates alcohol-seeking in rats. Br J Pharmacol 148:752\u2013729. https:\/\/doi.org\/10.1038\/sj.bjp.0706789","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"6767_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/NDT.S19617","volume":"7","author":"JP L\u00e9pine","year":"2011","unstructured":"L\u00e9pine JP, Briley M (2011) The increasing burden of depression. Neuropsychiatr Dis Treat 7(Suppl 1):3\u20137. https:\/\/doi.org\/10.2147\/NDT.S19617","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6767_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2021.105317","volume":"131","author":"B Li","year":"2021","unstructured":"Li B, Chang L, Peng X (2021) Orexin 2 receptor in the nucleus accumbens is critical for the modulation of acute stress-induced anxiety. Psychoneuroendocrinology 131:105317. https:\/\/doi.org\/10.1016\/j.psyneuen.2021.105317","journal-title":"Psychoneuroendocrinology"},{"key":"6767_CR65","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1001\/jamaneurol.2014.2510","volume":"71","author":"C Liguori","year":"2014","unstructured":"Liguori C, Romigi A, Nuccetelli M, Zannino S, Sancesario G, Martorana A, Albanese M, Mercuri NB, Izzi F, Bernardini S, Nitti A, Sancesario GM, Sica F, Marciani MG, Placidi F (2014) Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. JAMA Neurol 71:1498\u20131505. https:\/\/doi.org\/10.1001\/jamaneurol.2014.2510","journal-title":"JAMA Neurol"},{"key":"6767_CR66","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/s0092-8674(00)81965-0","volume":"98","author":"L Lin","year":"1999","unstructured":"Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365\u2013376. https:\/\/doi.org\/10.1016\/s0092-8674(00)81965-0","journal-title":"Cell"},{"key":"6767_CR67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.yfrne.2009.07.001","volume":"31","author":"M L\u00f3pez","year":"2010","unstructured":"L\u00f3pez M, Tena-Sempere M, Di\u00e9guez C (2010) Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes). Front Neuroendocrinol 31:113\u2013127. https:\/\/doi.org\/10.1016\/j.yfrne.2009.07.001","journal-title":"Front Neuroendocrinol"},{"key":"6767_CR68","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainres.2016.01.049","volume":"1636","author":"MF Lopez","year":"2016","unstructured":"Lopez MF, Moorman DE, Aston-Jones G, Becker HC (2016) The highly selective orexin\/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice. Brain Res 1636:74\u201380. https:\/\/doi.org\/10.1016\/j.brainres.2016.01.049","journal-title":"Brain Res"},{"key":"6767_CR69","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/schbul\/sbab042","volume":"47","author":"J Lu","year":"2021","unstructured":"Lu J, Huang ML, Li JH, Jin KY, Li HM, Mou TT, Fronczek R, Duan JF, Xu WJ, Swaab D, Bao AM (2021) Changes of Hypocretin (Orexin) System in Schizophrenia: From Plasma to Brain. Schizophr Bull 47:1310\u20131319. https:\/\/doi.org\/10.1093\/schbul\/sbab042","journal-title":"Schizophr Bull"},{"key":"6767_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2023.114497","volume":"450","author":"EB Maness","year":"2023","unstructured":"Maness EB, Blumenthal SA, Burk JA (2023) Dual orexin\/hypocretin receptor antagonism attenuates NMDA receptor hypofunction-induced attentional impairments in a rat model of schizophrenia. Behav Brain Res 450:114497. https:\/\/doi.org\/10.1016\/j.bbr.2023.114497","journal-title":"Behav Brain Res"},{"key":"6767_CR71","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/cne.1190","volume":"435","author":"JN Marcus","year":"2001","unstructured":"Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6\u201325. https:\/\/doi.org\/10.1002\/cne.1190","journal-title":"J Comp Neurol"},{"key":"6767_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/psyg.12314","volume":"18","author":"T Masuyama","year":"2018","unstructured":"Masuyama T, Sanui M, Yoshida N, Iizuka Y, Ogi K, Yagihashi S, Nagatomo K, Sasabuchi Y, Lefor AK (2018) Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Psychogeriatrics 18:209\u2013215. https:\/\/doi.org\/10.1111\/psyg.12314","journal-title":"Psychogeriatrics"},{"key":"6767_CR73","doi-asserted-by":"publisher","unstructured":"Matsuoka A, Tobita S, Sogawa R, Shinada K, Murakawa-Hirachi T, Shimanoe C, Monji A, Mizoguchi Y, Miike T, Sakamoto Y (2022) Evaluation of Suvorexant and Lemborexant for the Prevention of Delirium in Adult Critically Ill Patients at an Advanced Critical Care Center: A Single-Center, Retrospective, Observational Study. J Clin Psychiatry 84:22m14471. https:\/\/doi.org\/10.4088\/JCP.22m14471.","DOI":"10.4088\/JCP.22m14471"},{"key":"6767_CR74","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.genhosppsych.2023.03.010","volume":"83","author":"A Matsuoka","year":"2023","unstructured":"Matsuoka A, Sogawa R, Murakawa-Hirachi T, Mizoguchi Y, Monji A, Shimanoe C, Shinada K, Koami H, Sakamoto Y (2023) Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: A single-center, retrospective, observational study. Gen Hosp Psychiatry 83:123\u2013129. https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.03.010","journal-title":"Gen Hosp Psychiatry"},{"key":"6767_CR75","doi-asserted-by":"publisher","unstructured":"Matzeu A, Martin-Fardon R (2020) Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats. Neuropharmacology 164:107906. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107906","DOI":"10.1016\/j.neuropharm.2019.107906"},{"key":"6767_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02846-5","author":"S Mesens","year":"2024","unstructured":"Mesens S, Kezic I, Van Der Ark P, Etropolski M, Pandina G, Benes H, Savitz A, Drevets WC (2024) Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-024-02846-5","journal-title":"Mol Psychiatry"},{"key":"6767_CR77","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","volume":"31","author":"M Mieda","year":"2011","unstructured":"Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T (2011) Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J Neurosci 31:6518\u20136526. https:\/\/doi.org\/10.1523\/JNEUROSCI.6506-10.2011","journal-title":"J Neurosci"},{"key":"6767_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/NSS.S201994","volume":"15","author":"MP Mogavero","year":"2023","unstructured":"Mogavero MP, Silvani A, Lanza G, DelRosso LM, Ferini-Strambi L, Ferri R (2023) Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations. Nat Sci Sleep 15:17\u201338. https:\/\/doi.org\/10.2147\/NSS.S201994","journal-title":"Nat Sci Sleep"},{"key":"6767_CR79","doi-asserted-by":"publisher","unstructured":"Mohammadkhani A, James MH, Pantazis CB, Aston-Jones G (2020) Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil. Brain Res 1731:146461. https:\/\/doi.org\/10.1016\/j.brainres.2019.146461","DOI":"10.1016\/j.brainres.2019.146461"},{"issue":"Pt A","key":"6767_CR80","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.brainres.2016.10.018","volume":"1654","author":"DE Moorman","year":"2017","unstructured":"Moorman DE, James MH, Kilroy EA, Aston-Jones G (2017) Orexin\/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly-motivated rats. Brain Res 1654(Pt A):34\u201342. https:\/\/doi.org\/10.1016\/j.brainres.2016.10.018","journal-title":"Brain Res"},{"key":"6767_CR81","doi-asserted-by":"publisher","unstructured":"Moreira-Junior EDC, Rowlett JK, Berro LF (2024) Suvorexant enhances oxycodone-induced respiratory depression in male rats. Drug Alcohol Depend 264:112434. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.112434","DOI":"10.1016\/j.drugalcdep.2024.112434"},{"key":"6767_CR82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1523\/JNEUROSCI.2761-05.2006","volume":"26","author":"M Narita","year":"2006","unstructured":"Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M, Sakurai T, Yanagisawa M, Nakamachi T, Shioda S, Suzuki T (2006) Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 26:398\u2013405. https:\/\/doi.org\/10.1523\/JNEUROSCI.2761-05.2006","journal-title":"J Neurosci"},{"key":"6767_CR83","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.neuropharm.2011.04.022","volume":"61","author":"M Nollet","year":"2011","unstructured":"Nollet M, Gaillard P, Minier F, Tanti A, Belzung C, Leman S (2011) Activation of orexin neurons in dorsomedial\/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 61:336\u2013346. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.04.022","journal-title":"Neuropharmacology"},{"key":"6767_CR84","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/npp.2012.70","volume":"37","author":"M Nollet","year":"2012","unstructured":"Nollet M, Gaillard P, Tanti A, Girault V, Belzung C, Leman S (2012) Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 37:2210\u20132221. https:\/\/doi.org\/10.1038\/npp.2012.70","journal-title":"Neuropsychopharmacology"},{"key":"6767_CR85","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbr.2017.12.002","volume":"346","author":"P \u00d6z","year":"2018","unstructured":"\u00d6z P, G\u00f6kalp HK, G\u00f6ver T, Uzbay T (2018) Dose-dependent and opposite effects of orexin A on prepulse inhibition response in sleep-deprived and non-sleep-deprived rats. Behav Brain Res 346:73\u201379. https:\/\/doi.org\/10.1016\/j.bbr.2017.12.002","journal-title":"Behav Brain Res"},{"key":"6767_CR86","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.peptides.2014.05.003","volume":"57","author":"M Palotai","year":"2014","unstructured":"Palotai M, Telegdy G, J\u00e1szber\u00e9nyi M (2014) Orexin A-induced anxiety-like behavior is mediated through GABA-ergic, \u03b1- and \u03b2-adrenergic neurotransmissions in mice. Peptides 57:129\u2013134. https:\/\/doi.org\/10.1016\/j.peptides.2014.05.003","journal-title":"Peptides"},{"key":"6767_CR87","doi-asserted-by":"publisher","first-page":"286","DOI":"10.5152\/pcp.2021.20011","volume":"31","author":"J Pan","year":"2021","unstructured":"Pan J, Chen G, Shan P, Chen C, Jiang D, Wang L, Li G, Chen M, Zhuo C, Fang T, Yu H (2021) Plasma Orexin Levels Related to Altered Brain Activity During Abstinence in Patients with Alcohol Dependence. Psychiatry Clin Psychopharmacol 31:286\u2013291. https:\/\/doi.org\/10.5152\/pcp.2021.20011","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"6767_CR88","doi-asserted-by":"publisher","first-page":"10607","DOI":"10.1523\/JNEUROSCI.2629-16.2018","volume":"38","author":"SM Perez","year":"2018","unstructured":"Perez SM, Lodge DJ (2018) Convergent inputs from the hippocampus and thalamus to the nucleus accumbens regulate dopamine neuron activity. J Neurosci 38:10607\u201310618. https:\/\/doi.org\/10.1523\/JNEUROSCI.2629-16.2018","journal-title":"J Neurosci"},{"key":"6767_CR89","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/ijnp\/pyaa080","volume":"24","author":"SM Perez","year":"2021","unstructured":"Perez SM, Lodge DJ (2021) Orexin modulation of VTA dopamine neuron activity: relevance to schizophrenia. Int J Neuropsychopharmacol 24:344\u2013353. https:\/\/doi.org\/10.1093\/ijnp\/pyaa080","journal-title":"Int J Neuropsychopharmacol"},{"key":"6767_CR90","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MS9.0000000000000788","volume":"86","author":"F Piri","year":"2023","unstructured":"Piri F, Salmani ME, Sepehri H (2023) Improvement of autistic-like behaviors in adult rats prenatally exposed to valproic acid through early suppression of orexin receptor. Ann Med Surg (Lond) 86:166\u2013171. https:\/\/doi.org\/10.1097\/MS9.0000000000000788","journal-title":"Ann Med Surg (Lond)"},{"key":"6767_CR91","doi-asserted-by":"publisher","unstructured":"Prajapati SK, Krishnamurthy S (2021) Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses. Behav Brain Res 399:113015. https:\/\/doi.org\/10.1016\/j.bbr.2020.113015","DOI":"10.1016\/j.bbr.2020.113015"},{"key":"6767_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jad.2024.01.045","volume":"350","author":"SK Prajapati","year":"2024","unstructured":"Prajapati SK, Ahmed S, Rai V, Gupta SC, Krishnamurthy S (2024) Suvorexant improves mitochondrial dynamics with the regulation of orexinergic and mTOR activation in rats exhibiting PTSD-like symptoms. J Affect Disord 350:24\u201338. https:\/\/doi.org\/10.1016\/j.jad.2024.01.045","journal-title":"J Affect Disord"},{"key":"6767_CR93","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41386-018-0292-5","volume":"44","author":"K Rasmussen","year":"2019","unstructured":"Rasmussen K, White DA, Acri JB (2019) NIDA\u2019s medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology 44:657\u2013659. https:\/\/doi.org\/10.1038\/s41386-018-0292-5","journal-title":"Neuropsychopharmacology"},{"key":"6767_CR94","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","volume":"9","author":"K Recourt","year":"2019","unstructured":"Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, Van Hove I, van Gerven J, Jacobs G, van Nueten L, Drevets W (2019) The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry 9:216. https:\/\/doi.org\/10.1038\/s41398-019-0553-z","journal-title":"Transl Psychiatry"},{"key":"6767_CR95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/wps.20611","volume":"18","author":"GM Reed","year":"2019","unstructured":"Reed GM, First MB, Kogan CS, Hyman SE, Gureje O, Gaebel W, Maj M, Stein DJ, Maercker A, Tyrer P, Claudino A, Garralda E, Salvador-Carulla L, Ray R, Saunders JB, Dua T, Poznyak V, Medina-Mora ME, Pike KM, Ayuso-Mateos JL, Kanba S, Keeley JW, Khoury B, Krasnov VN, Kulygina M, Lovell AM, de Jesus MJ, Maruta T, Matsumoto C, Rebello TJ, Roberts MC, Robles R, Sharan P, Zhao M, Jablensky A, Udomratn P, Rahimi-Movaghar A, Rydelius PA, B\u00e4hrer-Kohler S, Watts AD, Saxena S (2019) Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 18:3\u201319. https:\/\/doi.org\/10.1002\/wps.20611","journal-title":"World Psychiatry"},{"key":"6767_CR96","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.pcl.2011.03.009","volume":"58","author":"AM Reynolds","year":"2011","unstructured":"Reynolds AM, Malow BA (2011) Sleep and autism spectrum disorders. Pediatr Clin North Am 58:685\u2013698. https:\/\/doi.org\/10.1016\/j.pcl.2011.03.009","journal-title":"Pediatr Clin North Am"},{"key":"6767_CR97","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrn2092","volume":"8","author":"T Sakurai","year":"2007","unstructured":"Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci 8:171\u2013181. https:\/\/doi.org\/10.1038\/nrn2092","journal-title":"Nat Rev Neurosci"},{"key":"6767_CR98","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0092-8674(00)80949-6","volume":"92","author":"T Sakurai","year":"1998","unstructured":"Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573\u2013585. https:\/\/doi.org\/10.1016\/s0092-8674(00)80949-6","journal-title":"Cell"},{"key":"6767_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112455","volume":"384","author":"S Salehabadi","year":"2020","unstructured":"Salehabadi S, Abrari K, Elahdadi Salmani M, Nasiri M, Lashkarbolouki T (2020) Investigating the role of the amygdala orexin receptor 1 in memory acquisition and extinction in a rat model of PTSD. Behav Brain Res 384:112455. https:\/\/doi.org\/10.1016\/j.bbr.2019.112455","journal-title":"Behav Brain Res"},{"key":"6767_CR100","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","volume":"10","author":"G Salvadore","year":"2020","unstructured":"Salvadore G, Bonaventure P, Shekhar A, Johnson PL, Lord B, Shireman BT, Lebold TP, Nepomuceno D, Dugovic C, Brooks S, Zuiker R, Bleys C, Tatikola K, Remmerie B, Jacobs GE, Schruers K, Moyer J, Nash A, Van Nueten LGM, Drevets WC (2020) Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry 10:308. https:\/\/doi.org\/10.1038\/s41398-020-00937-9","journal-title":"Transl Psychiatry"},{"key":"6767_CR101","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","volume":"24","author":"A Savitz","year":"2021","unstructured":"Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, Drevets WC (2021) Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study. Int J Neuropsychopharmacol 24:965\u2013976. https:\/\/doi.org\/10.1093\/ijnp\/pyab050","journal-title":"Int J Neuropsychopharmacol"},{"key":"6767_CR102","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","volume":"51","author":"TE Scammell","year":"2011","unstructured":"Scammell TE, Winrow CJ (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51:243\u2013266. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100528","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"6767_CR103","doi-asserted-by":"publisher","first-page":"20260","DOI":"10.1073\/pnas.1320325110","volume":"110","author":"RM Sears","year":"2013","unstructured":"Sears RM, Fink AE, Wigestrand MB, Farb CR, de Lecea L, Ledoux JE (2013) Orexin\/hypocretin system modulates amygdala-dependent threat learning through the locus coeruleus. Proc Natl Acad Sci USA 110:20260\u201320265. https:\/\/doi.org\/10.1073\/pnas.1320325110","journal-title":"Proc Natl Acad Sci USA"},{"key":"6767_CR104","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00213-010-2127-x","volume":"215","author":"JR Shoblock","year":"2011","unstructured":"Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K, Palmer J, Bonaventure P, Carruthers NI, Lovenberg TW, Boggs J, Galici R (2011) Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology 215:191\u2013203. https:\/\/doi.org\/10.1007\/s00213-010-2127-x","journal-title":"Psychopharmacology"},{"key":"6767_CR105","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0163-7258(02)00171-7","volume":"94","author":"D Smart","year":"2002","unstructured":"Smart D, Jerman J (2002) The physiology and pharmacology of the orexins. Pharmacol Ther 94:51\u201361. https:\/\/doi.org\/10.1016\/s0163-7258(02)00171-7","journal-title":"Pharmacol Ther"},{"key":"6767_CR106","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/j.1460-9568.2012.08013.x","volume":"35","author":"RJ Smith","year":"2012","unstructured":"Smith RJ, Aston-Jones G (2012) Orexin\/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur J Neurosci 35:798\u2013804. https:\/\/doi.org\/10.1111\/j.1460-9568.2012.08013.x","journal-title":"Eur J Neurosci"},{"key":"6767_CR107","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fnins.2020.00691","volume":"14","author":"S Soya","year":"2020","unstructured":"Soya S, Sakurai T (2020a) Evolution of Orexin Neuropeptide System: Structure and Function. Front Neurosci 14:691. https:\/\/doi.org\/10.3389\/fnins.2020.00691","journal-title":"Front Neurosci"},{"key":"6767_CR108","doi-asserted-by":"publisher","unstructured":"Soya S, Sakurai T (2020b) Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit. Brain Res 1731:146037. https:\/\/doi.org\/10.1016\/j.brainres.2018.11.032","DOI":"10.1016\/j.brainres.2018.11.032"},{"key":"6767_CR109","doi-asserted-by":"publisher","first-page":"14549","DOI":"10.1523\/JNEUROSCI.1130-13.2013","volume":"33","author":"S Soya","year":"2013","unstructured":"Soya S, Shoji H, Hasegawa E, Hondo M, Miyakawa T, Yanagisawa M, Mieda M, Sakurai T (2013) Orexin receptor-1 in the locus coeruleus plays an important role in cue-dependent fear memory consolidation. J Neurosci 33:14549\u201314557. https:\/\/doi.org\/10.1523\/JNEUROSCI.1130-13.2013","journal-title":"J Neurosci"},{"key":"6767_CR110","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41467-017-01782-z","volume":"8","author":"S Soya","year":"2017","unstructured":"Soya S, Takahashi TM, McHugh TJ, Maejima T, Herlitze S, Abe M, Sakimura K, Sakurai T (2017) Orexin modulates behavioral fear expression through the locus coeruleus. Nat Commun 8:1606. https:\/\/doi.org\/10.1038\/s41467-017-01782-z","journal-title":"Nat Commun"},{"key":"6767_CR111","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1124\/pr.58.1.4","volume":"58","author":"R Spinazzi","year":"2006","unstructured":"Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG (2006) Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev 58:46\u201357. https:\/\/doi.org\/10.1124\/pr.58.1.4","journal-title":"Pharmacol Rev"},{"key":"6767_CR112","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.yhbeh.2013.12.014","volume":"65","author":"LG Staples","year":"2014","unstructured":"Staples LG, Cornish JL (2014) The orexin-1 receptor antagonist SB-334867 attenuates anxiety in rats exposed to cat odor but not the elevated plus maze: an investigation of Trial 1 and Trial 2 effects. Horm Behav 65:294\u2013300. https:\/\/doi.org\/10.1016\/j.yhbeh.2013.12.014","journal-title":"Horm Behav"},{"key":"6767_CR113","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00213-012-2736-7","volume":"223","author":"MA Steiner","year":"2012","unstructured":"Steiner MA, Lecourt H, Jenck F (2012) The brain orexin system and almorexant in fear-conditioned startle reactions in the rat. Psychopharmacology 223:465\u2013475. https:\/\/doi.org\/10.1007\/s00213-012-2736-7","journal-title":"Psychopharmacology"},{"key":"6767_CR114","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/cmdc.201300003","volume":"8","author":"MA Steiner","year":"2013","unstructured":"Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C (2013a) Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 8:898\u2013903. https:\/\/doi.org\/10.1002\/cmdc.201300003","journal-title":"ChemMedChem"},{"key":"6767_CR115","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.psyneuen.2012.07.016","volume":"38","author":"MA Steiner","year":"2013","unstructured":"Steiner MA, Sciarretta C, Brisbare-Roch C, Strasser DS, Studer R, Jenck F (2013b) Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology 38:560\u2013571. https:\/\/doi.org\/10.1016\/j.psyneuen.2012.07.016","journal-title":"Psychoneuroendocrinology"},{"key":"6767_CR116","doi-asserted-by":"publisher","unstructured":"Stoops WW, Strickland JC, Hatton KW, Hays LR, Rayapati AO, Lile JA, Rush CR (2022) Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans. Pharmacol Biochem Behav 220:173466. https:\/\/doi.org\/10.1016\/j.pbb.2022.173466","DOI":"10.1016\/j.pbb.2022.173466"},{"key":"6767_CR117","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/FBP.0000000000000731","volume":"34","author":"JC Strickland","year":"2023","unstructured":"Strickland JC, Hatton KW, Hays LR, Rayapati AO, Lile JA, Rush CR, Stoops WW (2023) Use of drug purchase tasks in medications development research: orexin system regulation of cocaine and drug demand. Behav Pharmacol 34:275\u2013286. https:\/\/doi.org\/10.1097\/FBP.0000000000000731","journal-title":"Behav Pharmacol"},{"key":"6767_CR118","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.biopsych.2008.02.022","volume":"64","author":"A Surget","year":"2008","unstructured":"Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G, Hen R, Belzung C (2008) Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry 64:293\u2013301. https:\/\/doi.org\/10.1016\/j.biopsych.2008.02.022","journal-title":"Biol Psychiatry"},{"key":"6767_CR119","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.brainres.2005.03.002","volume":"1044","author":"M Suzuki","year":"2005","unstructured":"Suzuki M, Beuckmann CT, Shikata K, Ogura H, Sawai T (2005) Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res 1044:116\u2013121. https:\/\/doi.org\/10.1016\/j.brainres.2005.03.002","journal-title":"Brain Res"},{"key":"6767_CR120","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pbb.2014.08.013","volume":"126","author":"K Takuma","year":"2014","unstructured":"Takuma K, Hara Y, Kataoka S, Kawanai T, Maeda Y, Watanabe R, Takano E, Hayata-Takano A, Hashimoto H, Ago Y, Matsuda T (2014) Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism. Pharmacol Biochem Behav 126:43\u201349. https:\/\/doi.org\/10.1016\/j.pbb.2014.08.013","journal-title":"Pharmacol Biochem Behav"},{"key":"6767_CR121","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5761\/atcs.oa.18-00038","volume":"25","author":"K Tamura","year":"2019","unstructured":"Tamura K, Maruyama T, Sakurai S (2019) Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting. Ann Thorac Cardiovasc Surg 25:26\u201331. https:\/\/doi.org\/10.5761\/atcs.oa.18-00038","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"6767_CR122","doi-asserted-by":"publisher","unstructured":"Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F (2017) The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. J Pharmacol Exp Ther 362:489\u2013503. https:\/doi.org\/https:\/\/doi.org\/10.1124\/jpet.117.241596.","DOI":"10.1124\/jpet.117.241596"},{"key":"6767_CR123","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.biopsych.2015.04.021","volume":"79","author":"M Ubaldi","year":"2016","unstructured":"Ubaldi M, Giordano A, Severi I, Li H, Kallupi M, de Guglielmo G, Ruggeri B, Stopponi S, Ciccocioppo R, Cannella N (2016) Activation of hypocretin-1\/orexin-A neurons projecting to the bed nucleus of the stria terminalis and paraventricular nucleus is critical for reinstatement of alcohol seeking by neuropeptide S. Biol Psychiatry 79:452\u2013462. https:\/\/doi.org\/10.1016\/j.biopsych.2015.04.021","journal-title":"Biol Psychiatry"},{"key":"6767_CR124","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","volume":"239","author":"M Uchiyama","year":"2022","unstructured":"Uchiyama M, Kambe D, Imadera Y, Kajiyama Y, Ogo H, Uchimura N (2022) Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology 239:2143\u20132154. https:\/\/doi.org\/10.1007\/s00213-022-06089-6","journal-title":"Psychopharmacology"},{"key":"6767_CR125","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.bbr.2014.10.028","volume":"278","author":"MW Vanderhaven","year":"2015","unstructured":"Vanderhaven MW, Cornish JL, Staples LG (2015) The orexin-1 receptor antagonist SB-334867 decreases anxiety-like behavior and c-Fos expression in the hypothalamus of rats exposed to cat odor. Behav Brain Res 278:563\u2013568. https:\/\/doi.org\/10.1016\/j.bbr.2014.10.028","journal-title":"Behav Brain Res"},{"key":"6767_CR126","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbr.2016.08.052","volume":"316","author":"H Wang","year":"2017","unstructured":"Wang H, Li S, Kirouac GJ (2017) Role of the orexin (hypocretin) system in contextual fear conditioning in rats. Behav Brain Res 316:47\u201353. https:\/\/doi.org\/10.1016\/j.bbr.2016.08.052","journal-title":"Behav Brain Res"},{"key":"6767_CR127","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41572-020-00223-4","volume":"6","author":"JE Wilson","year":"2020","unstructured":"Wilson JE, Mart MF, Cunningham C, Shehabi Y, Girard TD, MacLullich AMJ, Slooter AJC, Ely EW (2020) Delirium Nat Rev Dis Primers 6:90. https:\/\/doi.org\/10.1038\/s41572-020-00223-4","journal-title":"Delirium Nat Rev Dis Primers"},{"key":"6767_CR128","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1021\/acs.jmedchem.5b00217","volume":"58","author":"Y Yoshida","year":"2015","unstructured":"Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, Ueno T, Ozaki S, Yonaga M (2015) Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A potent and efficacious oral orexin receptor antagonist. J Med Chem 58:4648\u20134664. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00217","journal-title":"J Med Chem"},{"key":"6767_CR129","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnbeh.2017.00083","volume":"11","author":"S Yun","year":"2017","unstructured":"Yun S, Wennerholm M, Shelton JE, Bonaventure P, Letavic MA, Shireman BT, Lovenberg TW, Dugovic C (2017) Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice. Front Behav Neurosci 11:83. https:\/\/doi.org\/10.3389\/fnbeh.2017.00083","journal-title":"Front Behav Neurosci"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06767-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:50:18Z","timestamp":1757148618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06767-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":129,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["6767"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06767-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"6 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shigeyuki Chaki is a full-time employee of Taisho Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}